Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies, Cancer Genomics and Diagnostics, and Immunotherapy and Immune Responses.
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial
Parity and lactation induce T-cell-mediated breast cancer protection
Origins and impact of extrachromosomal DNA
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial
The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
The evolution of non-small cell lung cancer metastases in TRACERx
Body composition and lung cancer-associated cachexia in TRACERx
Computational pathology in cancer diagnosis, prognosis, and prediction – present day and prospects
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study
PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
The 2019 World Health Organization classification of tumours of the breast
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group
The T cell differentiation landscape is shaped by tumour mutations in lung cancer
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells
A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study